KVUE vs REGN · P/E 21, rev $15.12B vs P/E 14, rev $4.29B
Kenvue Inc. (KVUE) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Kenvue Inc. (KVUE) is a household & personal products company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
Latest reported KVUE revenue for 2025-12-28 was $15.12B. Net income was $1.47B. Revenue was down 2.1% from 2024-12-29 to 2025-12-28. KVUE currently screens at market cap $34.58B and trailing P/E 21.4.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
KVUE currently screens at market cap $34.58B and trailing P/E 21.4. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the KVUE and REGN stock pages for the full models.
Not investment advice.